ArticleJournal of managed care & specialty pharmacy2022

Is adding ribociclib to fulvestrant cost-effective in treating postmenopausal women with HR+/HER2- advanced or metastatic breast cancer? A US payer perspective cost utility analysis.

Kevin Berrios et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.